Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $21.75.

A number of research analysts have commented on the stock. Canaccord Genuity Group reduced their price target on shares of Ventyx Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Wednesday, March 13th. Oppenheimer upgraded shares of Ventyx Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 price target on the stock in a research report on Tuesday, March 12th. Wells Fargo & Company upgraded shares of Ventyx Biosciences from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Finally, Lifesci Capital upgraded shares of Ventyx Biosciences from a "market perform" rating to an "outperform" rating in a research report on Wednesday, February 28th.

Ventyx Biosciences Stock Performance

VTYX traded down $0.15 on Thursday, reaching $4.60. The company had a trading volume of 1,292,157 shares, compared to its average volume of 4,052,531. The business has a 50 day simple moving average of $5.61 and a 200 day simple moving average of $7.74. The company has a market cap of $272.55 million, a price-to-earnings ratio of -1.39 and a beta of 0.27. Ventyx Biosciences has a 52-week low of $1.87 and a 52-week high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same quarter in the previous year, the company earned ($0.62) earnings per share. As a group, equities research analysts predict that Ventyx Biosciences will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VTYX. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Ventyx Biosciences by 139.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 63,944 shares of the company's stock worth $2,221,000 after acquiring an additional 37,240 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in Ventyx Biosciences by 962.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 987,970 shares of the company's stock worth $34,312,000 after acquiring an additional 895,000 shares during the period. Hudson Bay Capital Management LP lifted its stake in Ventyx Biosciences by 160.2% in the third quarter. Hudson Bay Capital Management LP now owns 248,515 shares of the company's stock worth $8,631,000 after acquiring an additional 153,000 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Ventyx Biosciences by 42.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 363,385 shares of the company's stock worth $12,620,000 after acquiring an additional 107,997 shares during the period. Finally, FMR LLC lifted its stake in Ventyx Biosciences by 1.5% in the third quarter. FMR LLC now owns 8,677,529 shares of the company's stock worth $301,371,000 after acquiring an additional 124,298 shares during the period. Institutional investors own 97.88% of the company's stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.